Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00035425 |
This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria)
Condition | Intervention | Phase |
---|---|---|
Neutropenia Fever Gram-Positive Bacterial Infections Neoplasms |
Drug: Antibiotic Drug: Vancomycin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment |
Ages Eligible for Study: | 13 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | M/1260/0079 |
Study First Received: | May 3, 2002 |
Last Updated: | February 17, 2006 |
ClinicalTrials.gov Identifier: | NCT00035425 |
Health Authority: | United States: Food and Drug Administration |
Pharmacia |
Fever Bacterial Infections Neutropenia Gram-Positive Bacterial Infections Hematologic Diseases |
Agranulocytosis Vancomycin Leukocyte Disorders Leukopenia Granulocytopenia |
Anti-Infective Agents Anti-Bacterial Agents Communicable Diseases Neoplasms |
Therapeutic Uses Infection Pharmacologic Actions |